Dermatology

Top Story

Funding for medical research and public health must reflect reality

Funding for medical research and public health must reflect reality
Infectious Disease News, July 2017
William Powderly, MD

The last few years have seen a growing force of infectious disease challenges that together pose an unprecedented range of threats to health here in the United States and in countries around the world where Americans travel and conduct business. While outbreaks of Ebola, Zika, SARS and MERS have spread from their places of origin with devastating impacts, rising rates of resistance to antimicrobial drugs threaten the gains of modern medicine at home and globally. New and re-emerging diseases with pandemic potential continue to surface, and diseases that include tuberculosis, once considered all but conquered, have evolved faster than the medicines to control them, to pose new dangers.

The Infectious Diseases Society of America, the oldest and largest association of physicians, scientists and other health care professionals specializing in preventing and treating transmissible illnesses, has recognized these threats. We have worked for more than a decade to raise awareness that antibiotic development is falling far short of need, and urged accelerated and immediate action in research, education, training, evidence-based practice and informed medical stewardship to improve our capacities to detect, prevent and respond to infectious diseases at home and abroad. We recognize that when medical research lags, pathogens gain ground, and that in an increasingly connected world, we cannot afford the costs that infections that are not countered by effective interventions inflict on families and communities, on individual and public health. And we are concerned because the budget proposal released by the Trump administration for the coming fiscal year does not reflect recognition of any of these realities.

FDA approves Baxdela for ABSSSIs; more treatments in the pipeline

Infectious Disease News, July 2017
The FDA recently approved an IV and oral formulation of Baxdela, an anionic fluoroquinolone, for the treatment of acute bacterial skin and skin structure infections, or…

Antimicrobial resistance over 3 decades: Moving toward a post-antibiotic era

Infectious Disease News, July 2017
To mark our 30th anniversary, Infectious Disease News will be examining some of the infectious diseases that have defined and changed the field over the past 3

Oral ABSSSI treatment omadacycline meets primary endpoints in phase 3 trial

July 19, 2017
Paratek Pharmaceuticals recently announced that its investigational antibiotic omadacycline — a once-daily, oral treatment for acute bacterial skin and skin…
More Headlines »
CME CE CNE CPE CPE

HIV/AIDS 1 Hour Update For Florida Health Professionals

No commercial support for this activity.

This is a 1 hour activity designed for home study by healthcare clinicians. Specifically, it meets the 1 hour HIV/AIDS…
More »
Meeting News

Taksta noninferior to Zyvox in treating ABSSSIs, including MRSA

June 4, 2017
NEW ORLEANS — Taksta was noninferior to Zyvox as an oral treatment for acute bacterial skin and skin structure…
More »
Resource Centers
ASM Microbe

ASM Microbe

Video
Meeting News Coverage

VIDEO: Recent advances made in leishmaniasis vaccine development

October 27, 2015
More »
Advertisement
Advertisement